Infliximab: Lifetime use for maintenance is appropriate in Crohn's disease. PRO: Maintenance therapy is superior to episodic therapy

American Journal of Gastroenterology

Volumn 100, Issue 7, 2005, Pages 1433-1435

  Lichtenstein, Gary R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CORTICOSTEROID; DNA ANTIBODY; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ARTHRALGIA; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE EXACERBATION; DRUG SAFETY; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION; INJECTION SITE REACTION; LONG TERM CARE; LUPUS ERYTHEMATOSUS; MAINTENANCE THERAPY; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; REMISSION; SHORT SURVEY; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; UNITED STATES;

ANTIBODIES; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS;

EID: 22744441489     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.50622_1.x     Document Type: Short Survey

References (20)

1. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96(3):635-43.
2. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99(4):956-63.
3. Brookes MJ, Green JR. Maintenance of remission in Crohn's disease: Current and emerging therapeutic options. Drugs 2004;64(10):1069-89.
4. Feagan BG. Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol 2003;98(Suppl 12):S6-17.
5. Gordon JN, MacDonald TT. Biological therapy in Crohn's disease. Hosp Med 2003;64(12):708-12.
6. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: First anniversary clinical experience. Am J Gastroenterol 2000;95(12):3469-77.
7. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999;353(9151):459-61.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359(9317):1541-9.
9. Feagan B. Infliximab in the treatment of Crohn's disease. Can J Gastroenterol 2000;14(Suppl C):6C.
10. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340(18):1398-405.
11. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95(12):3490-7.
12. Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003;98(10):2232-8.
13. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337(15):1029-35.
14. Sartor RB. Episodic retreatment versus scheduled maintenance therapy of Crohn's disease with infliximab: Not so far apart. Gastroenterology 2004;126(2):598-601.
15. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126(2):402-13.
16. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350(9):876-85.
17. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2(7):542-53.
18. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: A payor perspective. Am J Gastroenterol 2000;95(8):1955-60.
19. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol 2000;95(2):524-30.
20. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: Long-term efficacy and toxicity. Am J Gastroenterol 2000;95(7):1730-A